Jul 2, 2026 04:05PM
Jun 30, 2026 07:56AM
Jun 2, 2026 04:05PM
May 13, 2026 04:01PM
May 8, 2026 04:15PM
May 7, 2026 08:00AM
Apr 7, 2026 04:15PM vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Mar 16, 2026 08:00AM
Mar 12, 2026 06:43AM
Mar 10, 2026 04:01PM
Feb 13, 2026 08:00AM
Feb 2, 2026 08:01AM
Feb 2, 2026 08:00AM
Dec 18, 2025 04:05PM VTV Therapeutics submits phase 2 diabetes study protocol to UAE regulators
Dec 18, 2025 04:05PM
Nov 6, 2025 04:15PM
Oct 9, 2025 08:00AM
Oct 9, 2025 08:00AM
Sep 2, 2025 08:00AM
Sep 2, 2025 08:00AM
Aug 11, 2025 08:00AM vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin
Aug 7, 2025 08:00AM
Aug 7, 2025 08:00AM
May 15, 2025 12:00PM
May 15, 2025 12:00PM
Apr 9, 2025 06:03AM
Mar 20, 2025 05:35PM
Mar 17, 2025 08:30AM vTv Therapeutics (VTVT) Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes
Mar 17, 2025 08:30AM
Dec 9, 2024 07:33AM
Nov 12, 2024 04:05PM
Aug 8, 2024 04:15PM
Jul 26, 2024 04:05PM
Jul 26, 2024 04:05PM
Jun 24, 2024 04:08PM vTv Therapeutics (VTVT) Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes
Jun 24, 2024 04:05PM
May 28, 2024 08:00AM
May 20, 2024 12:00PM
May 9, 2024 04:51PM
Mar 19, 2024 08:30AM
Mar 13, 2024 08:00AM
Mar 4, 2024 08:00AM vTv Therapeutics (VTVT) Announces FDA Submission for First Phase 3 Study of Cadisegliatin
Mar 4, 2024 08:00AM
Nov 2, 2023 08:05AM
Nov 2, 2023 08:00AM
Aug 11, 2023 04:31PM
Aug 11, 2023 04:30PM
Aug 10, 2023 08:33AM
Jun 16, 2023 08:03AM vTv Therapeutics (VTVT) Reports Cantex Pharmaceuticals Licenses Exclusive Rights to Intellectual Property from Georgetown University for Azeliragon
Jun 16, 2023 08:00AM

325,297 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All